Canadian Hodgkin Lymphoma drug market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Hodgkin’s lymphoma is a malignant tumor that develops from cells in the lymphatic system called lymphocytes. The cancer is characterized histologically by the presence of multinucleated giant cells called Reed-Sternberg cells and associated abnormal, smaller mononuclear cells originating from B-lymphocytes in the germinal center’s lymphoid tissue. Hodgkin lymphoma is a relatively rare cancer. It accounts for around 0.5 % of all cancers and 15 % of all lymphomas diagnosed. In 2020, an estimated 1,000 Canadians were diagnosed, and 100 died from Hodgkin lymphoma. Hodgkin lymphoma occurs more frequently in males than females. The significant drivers are a large population base and increasing incidence rate, along with government support.
The increasing prevalence of cancers of different forms, including blood cancer, will aid the lymphoma treatment market growth during the forecast period. The growing necessity for advanced and effective therapeutics can be a crucial factor in boosting the lymphoma treatment market trends. For instance, lymphomas usually have no to minimal symptoms until cancer hits the last stage. In that period, aggressive and efficient therapeutics are required for better clinical outcomes. Furthermore, the requirement for pre-treatment options to administer advanced therapeutics in patients to treat lymphoma will enable the market’s healthy growth in the foreseeable future. A more robust treatment method fuels the growth of this market.